All patients
age >= 60 yr age >= 65 yr corticosteroids: no corticosteroids: yes invasive ventilation non invasive oxygen subjects at risk
antiviral and associated therapy in COVID 19 all comers - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results Jun C, 2020 1.00 [0.02; 53.89]
1.00 [0.02 ; 53.89 ] Jun C, 2020 1 0% 30 NA not evaluable deathsdetailed results Chen, ChiCTR2000030054 - Chloroquine, 2020 0.66 [0.01; 35.52]
ChiCTR2000030054-HCQ (Chen), 2020 0.66 [0.01; 35.52]
Jun C, 2020 1.00 [0.02; 53.89]
Lou (FAVIPIRAVIR), 2020 1.12 [0.02; 62.74]
NOR-Solidarity (hydroxychloroquine), 2021 3.10 [0.29; 33.20]
1.44 [0.31 ; 6.63 ] Chen, ChiCTR2000030054 - Chloroquine, 2020, ChiCTR2000030054-HCQ (Chen), 2020, Jun C, 2020, Lou (FAVIPIRAVIR), 2020, NOR-Solidarity (hydroxychloroquine), 2021 5 0% 221 moderate serious deaths (time to event analysis only)detailed results NOR-Solidarity (hydroxychloroquine), 2021 3.10 [0.29; 33.20]
3.10 [0.29 ; 33.20 ] NOR-Solidarity (hydroxychloroquine), 2021 1 0% 112 NA not evaluable clinical deteriorationdetailed results Jun C, 2020 2.07 [0.06; 66.79]
2.07 [0.06 ; 66.79 ] Jun C, 2020 1 0% 30 NA not evaluable clinical improvementdetailed results Lou (FAVIPIRAVIR), 2020 1.25 [0.21; 7.62]
1.25 [0.21 ; 7.62 ] Lou (FAVIPIRAVIR), 2020 1 0% 19 NA not evaluable clinical improvement (14-day)detailed results Lou (FAVIPIRAVIR), 2020 1.25 [0.21; 7.62]
1.25 [0.21 ; 7.62 ] Lou (FAVIPIRAVIR), 2020 1 0% 19 NA not evaluable mechanical ventilationdetailed results Jun C, 2020 2.07 [0.06; 66.79]
2.07 [0.06 ; 66.79 ] Jun C, 2020 1 0% 30 NA not evaluable viral clearance detailed results Jun C, 2020 0.82 [0.36; 1.87]
Lou (FAVIPIRAVIR), 2020 0.18 [0.01; 4.75]
0.75 [0.34 ; 1.67 ] Jun C, 2020, Lou (FAVIPIRAVIR), 2020 2 0% 49 serious not evaluable viral clearance (time to event analysis only)detailed results Jun C, 2020 0.82 [0.36; 1.87]
0.82 [0.36 ; 1.87 ] Jun C, 2020 1 0% 30 NA not evaluable viral clearance by day 14detailed results Lou (FAVIPIRAVIR), 2020 0.18 [0.01; 4.75]
0.18 [0.01 ; 4.75 ] Lou (FAVIPIRAVIR), 2020 1 0% 19 NA not evaluable viral clearance by day 7detailed results Jun C, 2020 0.58 [0.14; 2.48]
0.58 [0.14 ; 2.48 ] Jun C, 2020 1 0% 30 NA not evaluable ICU admissiondetailed results Lou (FAVIPIRAVIR), 2020 5.43 [0.21; 139.89]
5.43 [0.21 ; 139.89 ] Lou (FAVIPIRAVIR), 2020 1 0% 19 NA not evaluable adverse eventsdetailed results Chen, ChiCTR2000030054 - Chloroquine, 2020 1.92 [0.31; 12.05]
1.92 [0.31 ; 12.05 ] Chen, ChiCTR2000030054 - Chloroquine, 2020 1 0% 30 NA not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-21 03:21 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 94
- treatments: 545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814
- roots T: 290
